This $593,860 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund research to develop polymer-phage nanoparticle conjugates for treating antibiotic-resistant wound biofilm infections. The principal investigators, Drs. Rotello and Patel, will synthesize novel homopolymers and block copolymers to create phage-polymer nanoparticles that can effectively penetrate and eradicate methicillin-resistant...
The University of Melbourne will receive $599,253 under a three-year Project Grant award from the Department of the Army Medical Command to develop antimicrobial peptide-selenium nanoparticle dressings. The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve warfighter health and transform civilian healthcare. Specifically, the University will conduct research to enhance burn wound healing and prevent...
This $361,237 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a new class of species-specific antimicrobial peptides called PNA-STAMPS to target Streptococcus pneumoniae (Spn), a major human pathogen. The project builds on preliminary data showing that fusing a broad-spectrum antimicrobial peptide (AMP) to an Spn-specific secreted peptide can selectively eliminate...
This $367,577 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to Adepthera LLC aims to develop a regenerative peptide therapy to accelerate pressure ulcer healing. Specifically, the award will fund research to identify an optimal formulation of a self-assembling adrenomedullin (ADM) analog gel that can improve local blood circulation and wound healing in aging and diabetic mouse models. The proposed therapy would be administered weekly or biweekly via...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $741,917 to West Virginia University Research Corporation to develop therapeutic antibodies for the treatment of multidrug-resistant Pseudomonas aeruginosa infections, with a focus on sepsis. The key objectives are to characterize the mechanism of action of a lead antibody candidate, formulate it into a multivalent...
Acatechol, Inc. was awarded a $274,982 National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant to develop an innovative anti-infective coating for Foley catheters. The project aims to create a hybrid coating that combines biofilm-repellent and antimicrobial properties to provide prolonged resistance against pathogen colonization and catheter-associated urinary tract infections (CAUTIs). This work is being conducted under the NSF Technology, Innovation, and...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Therapeutic Bandage Products, Inc. (Willington, CT) supports the development of an advanced wound care product to treat diabetic foot ulcers. The product utilizes a patented microneedle patch design that delivers three therapeutic agents to disinfect the wound, prevent bacterial biofilm reformation, and activate the immune system. Initial work will be conducted using...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $383,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Nebraska Medical Center (UNMC) to discover novel antimicrobial peptides that can effectively eliminate drug-resistant gram-negative bacteria. The project aims to elucidate the structure-activity relationship, toxicity, pharmacokinetics, and in vivo efficacy of a novel antimicrobial peptide called Verine...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $205,735 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop an antimicrobial blue light-activatable optical endotracheal tube to combat biofilms on endotracheal tubes. The key objectives of this 2-year grant project are to: 1) Conduct in vitro studies to determine the anti-biofilm efficacy of the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Rowan University a $474,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel, daptomycin-inspired antimicrobial peptides using non-canonical amino acids. The goal is to create peptide molecules that mimic the key antimicrobial properties of daptomycin, such as calcium binding and lipid membrane disruption, while improving resistance to degradation and optimizing the...